Impact of Vancomycin Exposure on Outcomes in Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia: Support for Consensus Guidelines Suggested Targets
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
BACKGROUND: High rates of vancomycin failure in methicillin-resistant Staphylococcus aureus (MRSA) infections have been increasingly reported over time. The primary objective of our study was to determine the impact of vancomycin exposure and outcomes in patients with MRSA bacteremia initially treated with vancomycin. METHODS: This was a single-center retrospective analysis of 320 patients with documented MRSA bacteremia initially treated with vancomycin from January 2005 through April 2010. Two methods of susceptibility, Etest and broth microdilution, were performed for all isolates to determine the correlation of susceptibility testing to patient outcomes. RESULTS: Among a cohort of 320 patients, more than half (52.5%) experienced vancomycin failure. Independent predictors of vancomycin failure in logistic regression included infective endocarditis (adjusted odds ratio [AOR], 4.55; 95% confidence interval [CI], 2.26-9.15), nosocomial-acquired infection (AOR, 2.19; 95% CI, 1.21-3.97), initial vancomycin trough <15 mg/L (AOR, 2.00; 95% CI, 1.25-3.22), and vancomycin minimum inhibitory concentration (MIC) >1 mg/L by Etest (AOR, 1.52; 95% CI, 1.09-2.49). With use of Classification and Regression Tree (CART) analysis, patients with vancomycin area under the curve at 24 h (AUC(24h)) to MIC ratios <421 were found to have significantly higher rates of failure, compared with patients with AUC(24h) to MIC ratios >421 (61.2% vs 48.6%; P = .038). CONCLUSIONS: In light of the high failure rates associated with this antimicrobial, optimizing the pharmacokinetic/pharmacodynamic properties of vancomycin by targeting higher trough values of 15-20 mg/L and AUC(24h)/MIC ratios ≥400 in selected patients should be considered.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
System, A. R. F. T. N. (2003) · American Journal of Infection Control · doi:10.1016/j.ajic.2003.09.002 · Cited by 2,915
Lina, G., Piemont, Y., Godail-Gamot, F., Bes, M., Peter, M.-O., Gauduchon, V., Vandenesch, F., & Etienne, J. (1999) · Clinical Infectious Diseases · doi:10.1086/313461 · Cited by 2,489 · cited 1×
“genes encoding Panton–Valentine leukocidin, and agr group and agr function were determined using previously described methods [24, 25].”
MethodSystem, A. R. F. T. N. (2004) · American Journal of Infection Control · doi:10.1016/j.ajic.2004.10.001 · Cited by 2,342
Federal Funding for the Study of Antimicrobial Resistance in Nosocomial Pathogens: No ESKAPE
Rice, L. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/533452 · Cited by 2,310
Zhang, K., McClure, J.-A., Elsayed, S., Louie, T., & Conly, J. M. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.10.5026-5033.2005 · Cited by 1,037
Cosgrove, S. E., Qi, Y., Kaye, K. S., Harbarth, S., Karchmer, A. W., & Carmeli, Y. (2005) · Infection Control & Hospital Epidemiology · doi:10.1086/502522 · Cited by 856
Levine, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/491709 · Cited by 838
Self-citationSakoulas, G., Moise-Broder, P. A., Schentag, J., Forrest, A., Moellering, R. C., & Eliopoulos, G. M. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.6.2398-2402.2004 · Cited by 836
The emergence and evolution of methicillin-resistant Staphylococcus aureus
Hiramatsu, K., Cui, L., Kuroda, M., & Ito, T. (2001) · Trends in Microbiology · doi:10.1016/s0966-842x(01)02175-8 · Cited by 825
Cited by
Items 201–300 of 460
Bhalodi, A. A., Hagihara, M., Nicolau, D. P., & Kuti, J. L. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01516-13 · Cited by 19
“These ratios are much lower than the targeted total drug AUC/MIC ratio of 400, which is advocated for serious MRSA infections (3, 5).”
BackgroundOptimisation of Antimicrobial Dosing Based on Pharmacokinetic and Pharmacodynamic Principles
Hoo, G. S. R., Liew, Y. X., & Kwa, A. L. (2017) · Indian Journal of Medical Microbiology · doi:10.4103/ijmm.ijmm_17_278 · Cited by 25
Advances in antibacterial treatment of adults with high-risk febrile neutropenia
Contejean, A., Maillard, A., Canouï, É., Kernéis, S., Fantin, B., Bouscary, D., Parize, P., García‐Vidal, C., & Charlier, C. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad166 · Cited by 19
High versus low vancomycin serum trough regimen for Gram-positive infections: a meta-analysis
Meng, L., Fang, Y., Chen, Y., Zhu, H., & Long, R. (2014) · Journal of Chemotherapy · doi:10.1179/1973947814y.0000000182 · Cited by 20
Identifying determinants of persistent MRSA bacteremia using mathematical modeling
Mikkaichi, T., Yeaman, M. R., Hoffmann, A., & MRSA Systems Immunobiology Group (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007087 · Cited by 22
“However, such treatments fail in about 30–50% of patients, resulting in persistent bacteremia [4,5].”
BackgroundDrug dosing considerations in continuous renal replacement therapy
Jang, S. M., & Awdishu, L. (2021) · Seminars in Dialysis · doi:10.1111/sdi.12972 · Cited by 18
Lin, H. H., Bukovskaya, Y., de Moya, M., Lee, J., & Schmidt, U. H. (2015) · Annals of Intensive Care · doi:10.1186/s13613-015-0048-x · Cited by 19
“Despite the results of several studies that have concluded that an area under the curve (AUC)/minimum inhibitory concentration (MIC) ratio above 400 is required to achieve successful treatment for Methicillin-resistant Staphylococcus aureus (MRSA) infection [12-14], the general recommendations for MRSA infections are…”
BackgroundBritt, N. S., Patel, N., Horvat, R. T., & Steed, M. E. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02714-15 · Cited by 18
“An AUC/ MIC ratio of 421 also has been associated with clinical success in MRSA-B (12).”
BackgroundLacave, G., Caille, V., Bruneel, F., Palette, C., Legriel, S., Grimaldi, D., Eurin, M., & Bédos, J. (2017) · Medicine · doi:10.1097/md.0000000000006023 · Cited by 18
“Factors independently associated with AKI were highest serum vancomycin ≥40mg/L (odds ratio [OR], 3.75; 95% confidence interval [CI], 1.40–10.37; P< 0.01), higher cumulative number of organ failures (OR, 2.63 95%CI, 1.42–5.31; P<0.01), and cirrhosis of the liver (OR, 5.58; 95%CI, 1.08–31.59;…”
BackgroundInfluentialTruong, J. Q., Smith, S. R., Veillette, J. J., & Forland, S. C. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1273 · Cited by 18
Ono, T., Sugiyama, K., Komatsu, S., Kumano, M., Yoshida, K., Dairaku, T., Fujimura, T., Sasano, Y., Iwabuchi, Y., Kashiwagi, Y., et al. (2021) · RSC Advances · doi:10.1039/d1ra03681e · Cited by 17
Therapeutic Drug Monitoring–the Appropriate Use of Drug Level Measurement in the Care of the Neonate
Young, T. E. (2012) · Clinics in Perinatology · doi:10.1016/j.clp.2011.12.009 · Cited by 21
VANCOMYCIN: THE TALE OF THE VANQUISHER AND THE PYRRHIC VICTORY
Vriese, A. S. D., & Vandecasteele, S. J. (2014) · Peritoneal Dialysis International · doi:10.3747/pdi.2014.00001 · Cited by 19
“Thus far, only limited data on the effect of these more intensive dosing regimens are available, and they suggest that maintenance of higher vancomycin trough values improves clinical outcome (24).”
BackgroundMaraolo, A. E., Gatti, M., Principe, L., Marıno, A., Pipitone, G., PASCALE, G. D., & Ceccarelli, G. (2025) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2025.2487163 · Cited by 19
Host-Targeted Therapeutics against Multidrug Resistant Intracellular Staphylococcus aureus
Bravo-Santano, N., Behrends, V., & Letek, M. (2019) · Antibiotics · doi:10.3390/antibiotics8040241 · Cited by 18
“Moreover, clinical infection relapse is not uncommon, suggesting that the intracellular survival of these bacteria facilitates their resistance to the immune system and current antibiotherapies [18].”
BackgroundChattaweelarp, T., Changpradub, D., Punyawudho, B., Thunyaharn, S., & Santimaleeworagun, W. (2020) · Antibiotics · doi:10.3390/antibiotics9100672 · Cited by 18
Methicillin-Resistant Staphylococcus aureus and Vancomycin: Minimum Inhibitory Concentration Matters
Deresinski, S. C. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir932 · Cited by 16
“aureus pneumonia [4] and MRSA bacteremia [5, 6].”
Burnham, J. P., Burnham, C. D., Warren, D. K., & Kollef, M. H. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00925-16 · Cited by 16
Peyko, V., & Friedman-Jakubovics, M. (2018) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp160760 · Cited by 16
Zhang, T., Cheng, H., Pan, Z., Mi, J., Dong, Y., Zhang, Y., Sun, D., Du, Q., Cheng, X., & Dong, Y. (2019) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13303 · Cited by 19
Scully, P. T., Lam, W. M., Munoz, A. J. C., & Modem, V. (2022) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000002918 · Cited by 16
“The requirement for higher dosing of vancomycin is known in critically ill adult patients with ARC (2), and failure to achieve therapeutic concentrations may lead to treatment failure, worsening of sepsis, and bacterial resistance (5, 6).”
BackgroundKethireddy, S., & Kumar, A. (2012) · Yearbook of Critical Care Medicine · doi:10.1016/j.yccm.2012.01.020 · Cited by 16
Okada, N., Chuma, M., Azuma, M., Nakamura, S., Miki, H., Hamano, H., Goda, M., Takechi, K., Zamami, Y., Abe, M., et al. (2019) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-019-02756-4 · Cited by 16
“Serum VCM concentration is related to the incidence of VCM-induced AKI; the risk of VCMinduced AKI was reported to increase in patients with a VCM trough concentration of > 20 mg/L [15, 16].”
BackgroundQian, X., Guan-tao, D., Weng, C., Zhou, H., & Zhou, X. (2017) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2017.04.018 · Cited by 15
Alaniz, C., & Pogue, J. M. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r221 · Cited by 15
Koh, Y. R., Kim, K.-H., Chang, C. L., & Yi, J. (2016) · Annals of Laboratory Medicine · doi:10.3343/alm.2016.36.3.235 · Cited by 16
“A significant association between the initial vancomycin trough level and vancomycin treatment failure was reported previously [39].”
60 Plus Years Later and We Are Still Trying to Learn How to Dose Vancomycin
Rodvold, K. A. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz467 · Cited by 17
Canty, E. A., Carnahan, B., Curley, T. E., Anususinha, E., Hamdy, R. F., & Ericson, J. E. (2020) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000002992 · Cited by 19
“The pharmacodynamic parameter best associated with efficacy in clinical studies is a ratio of the area under the concentration curve at 24 hours (AUC 24 ) to vancomycin minimum inhibitory concentration (vMIC) >400.(2,3) Because the therapeutic target incorporates the MIC of the organism, infections caused by isolates…”
BackgroundCastañeda, X., García-de-la-Mària, C., Gasch, O., Pericàs, J. M., Soy, D., Cañas-Pacheco, M. A., Falces, C., García‐González, J., Meneses, M. H., Vidal, B., et al. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab069 · Cited by 17
Evaluation of the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia
Usery, J. B., Vo, N. H., Finch, C. K., Cleveland, K. O., Gelfand, M. S., & Self, T. H. (2014) · The American Journal of the Medical Sciences · doi:10.1097/maj.0000000000000338 · Cited by 17
Ramı́rez, E., Jiménez, C., Borobia, A. M., Tong, H. Y., Medrano, N., Krauel-Bidwell, L., Carcas, A. J., Selgas, R., & Frías, J. (2013) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e318286eb86 · Cited by 15
Joshi, M., O’Donnell, J. N., Venkatesan, N., Chang, J. H. T., Nguyen, H., Rhodes, N. J., Pais, G. M., Chapman, R., Griffin, B. L., & Scheetz, M. H. (2017) · Clinical and Translational Science · doi:10.1111/cts.12484 · Cited by 15
The comparative risk of acute kidney injury of vancomycin relative to other common antibiotics
Gaggl, M., Pate, V., Stürmer, T., Kshirsagar, A. V., & Layton, J. B. (2020) · Scientific Reports · doi:10.1038/s41598-020-73687-9 · Cited by 16
Uda, K., Suwa, J., Ito, K., Hataya, H., & Horikoshi, Y. (2019) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-24.5.450 · Cited by 14
Chua, H. C., & Tam, V. H. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac626 · Cited by 15
Lung and Serum Teicoplanin Concentration After Aerosol and Intravenous Administration in a Rat Model
Mercier, E., Darrouzain, F., Montharu, J., Guillon, A., Diot, P., Paintaud, G., & Vecellio, L. (2013) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2013.1060 · Cited by 14
“(24–26) This is unlikely to be achieved in clinical practice, because increasing the serum trough concentration involves increased risk of nephrotoxicity and ototoxicity.”
Chong, Y. P., Park, K., Kim, E. S., Kim, M., Kim, S., Lee, S., Choi, S., Jeong, J., Woo, J. H., & Kim, Y. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089139 · Cited by 14
“Vancomycin MICs of methicillin-resistant S. aureus (MRSA) isolates were determined by the vancomycin Etest (AB Biodisk, Piscataway, NJ, USA) on Mueller-Hinton agar according to the manufacturer’s instructions.”
BackgroundInfluentialMa, N. H., Walker, S. A. N., Elligsen, M., Kiss, A., Palmay, L., Ho, G., Powis, J. E., Bansal, V., & Leis, J. A. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz531 · Cited by 16
Significant publications on infectious diseases pharmacotherapy in 2011
Tran, T. T., Beyda, N. D., Biehle, L. R., Cottreau, J. M., Echevarria, K. L., Musick, W. L., Perez, K. K., & Schilling, A. N. (2012) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp120151 · Cited by 14
Makmor‐Bakry, M., Ahmat, A. N. M. F., Shamsuddin, A. F., Lau, C. L., & Ramli, R. (2019) · Anaesthesiology Intensive Therapy · doi:10.5114/ait.2019.87362 · Cited by 13
Hall, R. G., Blaszczyk, A. T., Thompson, K. A., Brouse, S. D., Giuliano, C. A., Frei, C. R., Forcade, N. A., Mortensen, E. M., Bell, T., Bedimo, R., et al. (2014) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12203 · Cited by 13
“The 26% mortality rate observed in our cohort is similar to that observed by other investigators.(18) ICU residence was the only factor significantly associated with in-hospital mortality in our cohort.”
ResultHoshino, S., Takeuchi, M., Kawakubo, H., Kobayashi, R., Matsuda, S., Irino, T., Fukuda, K., Nakamura, R., & Kitagawa, Y. (2022) · Esophagus · doi:10.1007/s10388-021-00901-6 · Cited by 13
“Several important cutoff values for antibiotics, such as vancomycin and Arbekacin, have been determined by CART analysis [20, 21].”
BackgroundVancomycin-associated acute kidney injury epidemiology in children: a systematic review
Williams, C., Hankinson, C., McWilliam, S. J., & Oni, L. (2022) · Archives of Disease in Childhood · doi:10.1136/archdischild-2021-323429 · Cited by 13
Comparative Analysis of Daptomycin and Vancomycin in the Treatment of Vertebral Osteomyelitis
Rangaraj, G., Cleveland, K. O., & Gelfand, M. S. (2013) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0000000000000116 · Cited by 13
“In a recently published study by Kullar et al11 of vancomycin therapy of MRSA bacteremia, 47 patients had a bone and/or joint concomitant site of infection.”
BackgroundMethodInfluentialSurgical Infections and Antibiotic Use
Barie, P. S. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1560-6.00012-3 · Cited by 15
Patel, N., Huang, D. B., & Lodise, T. P. (2018) · Clinical Drug Investigation · doi:10.1007/s40261-018-0686-5 · Cited by 13
Omrani, A. S., Mously, A., Cabaluna, M. P., Kawas, J., Albarrak, M. M., & Alfahad, W. A. (2014) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2014.08.005 · Cited by 13
“It has been shown that for optimal clinical outcomes, the ratio of area under the curve (AUC) of serum vancomycin concentration to bacterial minimum inhibitory concentration (MIC) should be maintained at 400 or above (Kullar et al., 2011; Rybak et al., 2009).”
BackgroundBush, L. M. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir528 · Cited by 13
“The recently published articles by Patel et al [1], Kullar et al [2], and Lubin et al [3] persuasively bolster the growing consensus opinion that the goldstandard antimicrobial agent for treatment of serious infections involving methicillinresistant Staphylococcus aureus (MRSA), vancomycin, has become tarnished.”
BackgroundHan, Z., Pettit, N. N., Landon, E. M., & Brielmaier, B. D. (2017) · Hospital Pharmacy · doi:10.1310/hpj5204-273 · Cited by 13
Methicillin-resistant Staphylococcus aureus bacteremia in hemodialysis and nondialysis patients
Kan, L., Lin, J., Chiu, S.-K., Yeh, Y.-C., Lin, T., Yang, Y., Wang, Y.-C., Wang, N., Yeh, K., & Chang, F. (2012) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2012.08.015 · Cited by 12
The case for precision dosing: medical conservatism does not justify inaction
Scheetz, M. H., Lodise, T. P., Downes, K. J., Drusano, G. L., & Neely, M. N. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab086 · Cited by 15
Haseeb, A., Alqurashi, M. K., Althaqafi, A. S., Alsharif, J. M., Faidah, H. S., Bushyah, M., Alotaibi, A. M. F., Elrggal, M. E., Mahrous, A. J., Abuhussain, S. S. A., et al. (2022) · Antibiotics · doi:10.3390/antibiotics11030409 · Cited by 12
Mazzitelli, M., Gatti, M., Scaglione, V., Mengato, D., Trevenzoli, M., Sattin, A., Pea, F., & Cattelan, A. M. (2022) · Antibiotics · doi:10.3390/antibiotics11101377 · Cited by 12
“However, it needs to be given intravenously on a twice daily basis (thus, requiring an indwelling catheter) for at least 6 weeks of the treatment, its serum concentrations must be carefully monitored, and its dose has to be adjusted accordingly to the renal function to prevent nephrotoxicity [20,21].”
BackgroundMartini, S., Tumietto, F., Sciutti, R., Greco, L., Faldella, G., & Corvaglia, L. (2015) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/s13052-015-0163-1 · Cited by 12
“Moreover, higher rates of treatment failure have also been observed in patients with MRSA bacteremia initially treated with vancomycin [12].”
BackgroundPrescribing Habits of Vancomycin in the Emergency Department: Are We Dosing Appropriately?
Rosini, J. M., Grovola, M. R., Levine, B. J., & Jasani, N. B. (2013) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2012.11.051 · Cited by 14
Downes, K. J., Zuppa, A. F., Sharova, A. P., & Neely, M. N. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051336 · Cited by 11
Frazier, J. D., Stoudenmire, L. L., Wagner, J. L., Thomas, G. M., Steele, G. M., Henao‐Martínez, A. F., Franco‐Paredes, C., & Chastain, D. B. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.106842 · Cited by 13
The Influence of a Therapeutic Drug Monitoring Service on Vancomycin‐Associated Nephrotoxicity
Yang, J. J., Brett, J., Sordo, A., Reuter, S. E., STOCKER, S. L., Day, R. O., Roberts, D. M., & Carland, J. E. (2023) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2363 · Cited by 11
Hoegy, D., Goutelle, S., Garnier, N., Renard, C., Faure‐Conter, C., Bergeron, C., Bertrand, Y., & Bleyzac, N. (2018) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12344 · Cited by 11
Evaluation for optimal dosing of vancomycin in patients with different physical types
Hashimoto, M., Iketani, O., Ichinose, N., Enoki, Y., Taguchi, K., Uno, S., Uwamino, Y., Hasegawa, N., & Matsumoto, K. (2019) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2019.04.017 · Cited by 11
Changing characteristics of S. aureus bacteremia caused by PVL-negative, MRSA strain over 11 years
Yang, E., Kim, E. S., Chung, H., Lee, Y. W., Bae, S., Jung, J., Kim, M. J., Chong, Y. P., Kim, S., Choi, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-95115-2 · Cited by 12
Wolff, M., & Mourvillier, B. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis330 · Cited by 11
Constantino, L. D. S., Guimarães, T. D. R., de Oliveira, S. Q., Bianco, Έ. M., Pessoa, L. G. D. S., Michels, M., Schenkel, E. P., Dal‐Pizzol, F., & Reginatto, F. H. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.023 · Cited by 9
Chander, S., Kumari, R., Wang, H. Y., Mohammed, Y. N., Parkash, O., Lohana, S., Sorath, F., Lohana, A. C., Sadarat, F., & Shiwlani, S. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09927-4 · Cited by 15
“An analysis by excluding three studies [44, 49] showed no heterogeneity among the other studies, implying that the high heterogeneity could be due to the high variability of patient data, i.e., serum creatine levels, receiving first vancomycin therapy a few days before the study and any other…”
MethodAn educational intervention to improve vancomycin prescribing and monitoring
Phillips, C. J., Doan, H., Quinn, S. J., Kirkpatrick, C. M. J., Gordon, D., & Doogue, M. P. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.11.010 · Cited by 10
Vancomycin MIC as a predictor of outcome in MRSA bacteraemia in the UK context
Hope, R., Blackburn, R. M., Verlander, N. Q., Johnson, A. P., Kearns, A., Hill, R., Hopkins, S., Sheridan, E., Livermore, D. M., Scarborough, M., et al. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt234 · Cited by 11
Wei, W., Qin, X., Cheng, D.-H., Lu, H., & Liu, T. (2016) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12437 · Cited by 10
“A recent study of Chinese adults with Gram-positive infection did not find any association between the vancomycin trough concentration and the clinical and microbiological responses.6 In addition, several meta-analyses have shown that higher vancomycin trough levels (15 mg/L or greater) were not associated with signif…”
ResultDownes, K. J., Zane, N. R., & Zuppa, A. F. (2020) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000796 · Cited by 12
“Subjects were excluded if they (1) had a preceding diagnosis of hypothyroidism or hyperthyroidism, because this can affect the CysC level,33 or (2) if they were receiving renal replacement therapy or extracorporeal membrane oxygenation.”
MethodViertel, K., Feles, E. A., Schulte, M., Annecke, T., & Mattner, F. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.107005 · Cited by 11
Vancomycin Treatment Failure in Children With Methicillin-Resistant Staphylococcus aureus Bacteremia
Regen, R. B., Schuman, S. S., Chhim, R. F., Arnold, S. R., & Lee, K. R. (2019) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-24.4.312 · Cited by 9
Does vancomycin have a future in the treatment of skin infections?
O’Brien, D. J., & Gould, I. M. (2014) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000048 · Cited by 10
Ramos, J. R., Ramírez, P., Concha, P., Salavert, M., Villarreal, E., Gordón, M., Frasquet, J., & Castellanos-Ortega, Á. (2018) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2018.03.007 · Cited by 9
Suzuki, H., Shomura, S., Sawada, Y., Shimamoto, A., Kondo, C., Takao, M., & Shimpo, H. (2019) · General Thoracic and Cardiovascular Surgery · doi:10.1007/s11748-019-01134-2 · Cited by 9
Validity of 2020 vancomycin consensus recommendations and further guidance for practical application
Rybak, M. J., Lê, J., Lodise, T. P., Levine, D. P., Bradley, J. S., Liu, C., Mueller, B. A., Pai, M. P., Beringer, A.-W., Rodvold, K. A., et al. (2021) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxab123 · Cited by 9
Self-citationKlompas, M. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00303-9 · Cited by 9
Smeets, T. J. L., de Geus, H. R. H., Rietveld, A., Rietdijk, W. J. R., Koch, B. C. P., Endeman, H., & Hunfeld, N. (2023) · Blood Purification · doi:10.1159/000530815 · Cited by 8
Cabanilla, M. G., Bernauer, M. L., Briski, M. J., Atallah, L. M., Koury, J., Thompson, C. M., Rodriguez, C. N., Jakeman, B., & Byrd, T. F. (2024) · Journal of Pharmacy Technology · doi:10.1177/87551225241227796 · Cited by 8
Vancomycin Area Under the Curve‐guided Dosing and Monitoring: “Is the Juice Worth the Squeeze”?
Lodise, T. P., Hall, R. G., & Scheetz, M. H. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2482 · Cited by 9
Marko, R., Hajjar, J. M., Nzeribe, V., Pittman, M., Deslandes, V., Sant, N., Cowan, J., Kyermentang, K., Ramsay, T., Zelenitsky, S. A., et al. (2021) · The Canadian Journal of Hospital Pharmacy · doi:10.4212/cjhp.v74i4.3195 · Cited by 8
Bédos, J., Allaouchiche, B., Armand-Lefèvre, L., Baldési, O., Bouadma, L., Decré, D., Figueiredo, S., Gauzit, R., Guery, B. P., Joram, N., et al. (2014) · Réanimation · doi:10.1007/s13546-014-0916-7 · Cited by 11
Impact of vancomycin treatment duration and dose on kidney injury
Bosch, K., McLaughlin, M. M., Esterly, J. S., Rhodes, N. J., Postelnick, M. J., & Scheetz, M. H. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.11.004 · Cited by 8
Modeling for critically ill patients: An introduction for beginners
Lafont, E., Urien, S., Salem, J., Heming, N., & Faisy, C. (2015) · Journal of Critical Care · doi:10.1016/j.jcrc.2015.09.002 · Cited by 9
Harmonizing antibiotic regimens with renal replacement therapy
Jang, S. M., Lewis, S. J., & Mueller, B. A. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1764845 · Cited by 8
Parra, D., Mesa, J. A. P., Cuervo, S. I., Díaz, J., Cortés, J. A., Silva, E. F., Saavedra, C., & Gómez-Rincón, J. C. (2022) · Antibiotics · doi:10.3390/antibiotics11111523 · Cited by 10
Miller, C. L., Winans, S. A., Veillette, J. J., & Forland, S. C. (2018) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-23.2.92 · Cited by 8
Are Blacks at Higher Risk for Vancomycin-Related Acute Kidney Injury?
Sharma, M., Braekevelt, K., Kale-Pradhan, P. B., Szpunar, S. M., & Khatib, R. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190018800093 · Cited by 8
Taccone, F. S., Vincent, J., Denis, O., & Jacobs, F. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis332 · Cited by 8
Tsuruyama, M., Yamashina, T., Tsuruta, M., Tsukada, H., Fujimoto, A., Nagano, M., Kawamata, Y., Takashima, S., & Hiraki, Y. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13197 · Cited by 7
Song, X., Zeng, M., Wu, Y. P., & Pan, Y. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.649757 · Cited by 8
Kim, Y. R., Chun, H.-J., Heo, J. Y., Yoo, J. S., Choi, Y. H., & Kim, E. J. (2022) · Current Therapeutic Research · doi:10.1016/j.curtheres.2022.100687 · Cited by 9
Kullar, R., Rybak, M. J., & Kaye, K. S. (2013) · Infection Control and Hospital Epidemiology · doi:10.1086/669868 · Cited by 8
“aureus are high.(15)"(19) Reports have correlated various factors, including older age and certain underlying disease states, as independent predictors of failure in vancomycin treatment of BSI due to MRSA.”
BackgroundSelf-citationÁlvarez, C. A., Giuliano, C. A., Haase, K. K., Thompson, K. A., Frei, C. R., Forcade, N. A., Brouse, S. D., Mortensen, E. M., Bell, T., Bedimo, R., et al. (2014) · The American Journal of the Medical Sciences · doi:10.1097/maj.0000000000000262 · Cited by 9
“The vancomycin trough cutoff of 15 mg/L was based on the guideline recommendations (15–20 mg/L) and data that suggest higher trough concentrations are associated with an increased incidence in nephrotoxicity.(5,20) The Pitt bacteremia score cutoff of 4 or higher was used based on previous literature demonstrating sign…”
BackgroundMethodResultBuckel, W. R., Ghobrial, S. S., Tamma, P. D., Milstone, A. M., Zhao, Y., & Hsu, A. J. (2016) · Pediatric Drugs · doi:10.1007/s40272-016-0202-4 · Cited by 7
Wilcox, M. H., Dmitrieva, N., Gales, A. C., Николаевна, П. И., Al-Obeid, S., Rossi, F., & Blondeau, J. M. (2017) · Future Microbiology · doi:10.2217/fmb-2017-0106 · Cited by 7
Vancomycin Pharmacokinetics in Patients with Advanced Cancer Near End of Life
Nakayama, H., Suzuki, M., Kato, T., & Echizen, H. (2019) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-019-00564-w · Cited by 7
Hamada, Y., Kuti, J. L., & Nicolau, D. P. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01553-15 · Cited by 7
Ceftobripole: Experience in staphylococcal bacteremia.
Soriano, À., & Morata, L. (2019) · PubMed Central · Cited by 7
Weston, A., & Boucher, H. W. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir777 · Cited by 7
Kondo, M., Nakagawa, S., Orii, S., Itohara, K., Sugimoto, M., Omura, T., Sato, Y., Imai, S., Yonezawa, A., Nakagawa, T., et al. (2020) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b19-01003 · Cited by 6
Metadata
- Authors
- Kullar, R., Davis, S. L., Levine, D. P., & Rybak, M. J.
- Affiliations
- Eugene Applebaum College of Pharmacy and Health Sciences (US)
- Wayne State University (US)
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-04-01
- Volume
- 52
- Issue
- 8
- Pages
- 975-981
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2099365065
- Semantic Scholar
- ed3c7f78a7e345dd4578c14051be67b5da32fd88
- Cited by
- 463
- References
- 44
- Citations by year
- 2026: 11 · 2025: 10 · 2024: 15 · 2023: 15 · 2022: 22 · 2021: 37 · 2020: 33 · 2019: 40 · 2018: 27 · 2017: 26 · 2016: 30 · 2015: 37 · 2014: 43 · 2013: 57 · 2012: 45
- FWCI
- 34.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Astellas Pharma
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- vancomycin, methicillin-resistant Staphylococcus aureus, MRSA bacteremia, pharmacokinetic/pharmacodynamic targets, AUC/MIC ratio, trough concentration, infective endocarditis, nosocomial infections, antimicrobial susceptibility testing, E-test, broth microdilution
- MeSH terms
- Anti-Bacterial Agents, Humans, Microbial Sensitivity Tests, Middle Aged, Retrospective Studies, Staphylococcal Infections, Vancomycin, Bacteremia, Treatment Outcome, Guidelines as Topic, Methicillin-Resistant Staphylococcus aureus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.